Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Qilu Pharmaceutical Co., Ltd.
OHSU Knight Cancer Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Incyte Corporation
National Cancer Institute (NCI)
AstraZeneca
OHSU Knight Cancer Institute
MOMA Therapeutics
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Cambridge University Hospitals NHS Foundation Trust
Exelixis
AstraZeneca
Australasian Gastro-Intestinal Trials Group
University of Colorado, Denver
Georgetown University
Asan Medical Center
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
Tango Therapeutics, Inc.
University Health Network, Toronto
Azienda Ospedaliero-Universitaria di Modena
Seoul National University Hospital
Seoul National University Hospital
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
AstraZeneca
Yale University
Canadian Cancer Trials Group
AstraZeneca
Ellipses Pharma
Sheba Medical Center
Grupo Espanol Multidisciplinario del Cancer Digestivo
AstraZeneca
Royal Marsden NHS Foundation Trust
AstraZeneca
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
AstraZeneca
The Christie NHS Foundation Trust